Found: 18
Select item for more details and to access through your institution.
Assessing cognitive toxicity in early phase trials ‐ What are we missing?
- Published in:
- Psycho-Oncology, 2022, v. 31, n. 3, p. 405, doi. 10.1002/pon.5834
- By:
- Publication type:
- Article
A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients.
- Published in:
- Cancer Reports, 2024, v. 7, n. 6, p. 1, doi. 10.1002/cnr2.2083
- By:
- Publication type:
- Article
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC).
- Published in:
- Cancers, 2024, v. 16, n. 6, p. 1218, doi. 10.3390/cancers16061218
- By:
- Publication type:
- Article
Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma.
- Published in:
- Sarcoma, 2010, p. 1, doi. 10.1155/2010/264360
- By:
- Publication type:
- Article
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets.
- Published in:
- Molecular Oncology, 2023, v. 17, n. 2, p. 230, doi. 10.1002/1878-0261.13327
- By:
- Publication type:
- Article
Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs.
- Published in:
- Research Involvement & Engagement, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40900-024-00599-7
- By:
- Publication type:
- Article
Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 22, p. 7943, doi. 10.1002/cam4.4307
- By:
- Publication type:
- Article
Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787).
- Published in:
- 2021
- By:
- Publication type:
- Abstract
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918786658
- By:
- Publication type:
- Article
A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
- Published in:
- PLoS ONE, 2019, v. 14, n. 11, p. 1, doi. 10.1371/journal.pone.0225509
- By:
- Publication type:
- Article
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
- Published in:
- PLoS ONE, 2022, v. 17, n. 7, p. 1, doi. 10.1371/journal.pone.0270950
- By:
- Publication type:
- Article
Ultra low dose thalidomide in elderly patients with myeloma.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
- Published in:
- Oncology, 2016, v. 90, n. 5, p. 280, doi. 10.1159/000444928
- By:
- Publication type:
- Article
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 1, p. 22, doi. 10.1002/onco.13976
- By:
- Publication type:
- Article
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
- Published in:
- PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0186106
- By:
- Publication type:
- Article